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Abstract
Objective
Use of growth hormone is associated with side effects, including insulin resistance. The
objective of this study was to determine whether tesamorelin, a stabilized growth hormone-
releasing hormone analogue, would alter insulin sensitivity or control of diabetes.
Design
A 12-week randomized, placebo-controlled study of 53 patients with type 2 diabetes. Three
treatment groups: placebo, 1 and 2 mg tesamorelin.
Measurements
Fasting glucose, glucose and insulin from oral glucose tolerance test, glycosylated hemo-
globin (HbA1c), home blood glucose, insulin-like growth factor-1, and lipids.
Main outcome measure
Relative insulin response following oral ingestion of glucose.
Results
No significant differences were observed between groups in relative insulin response over
the 12-week treatment period. At Week 12, fasting glucose, HbA1c and overall diabetes con-
trol were not significantly different between groups. In addition, relevant modifications in dia-
betes medications were similar between groups. Total cholesterol (-0.3±0.6 mmol/L) and
non-HDL cholesterol (-0.3±0.5 mmol/L) significantly decreased from baseline to Week 12 in
the tesamorelin 2 mg group (p<0.05 vs. placebo). No patient discontinued the study due to
loss of diabetes control.
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Conclusions
Treatment of type 2 diabetic patients with tesamorelin for 12 weeks did not alter insulin
response or glycemic control.
Trial registration
ClinicalTrials.gov NCT01264497.
Introduction
Recombinant human growth hormone (rhGH) replacement therapy has been shown to
reverse several metabolic alterations associated with low serum GH level or GH deficiency,
including increased visceral adipose tissue (VAT), altered lipid profile, and impaired physical
performance [1–3]. However, administration of pharmacological doses of rhGH is associated
with a variety of adverse effects, including hyperglycemia, insulin resistance, fluid retention,
and carpal tunnel syndrome [3–4]. In contrast, strategies using growth hormone-releasing fac-
tor (GRF)/growth hormone-releasing hormone (GHRH) analogues to induce physiological
increases of GH and preserve the insulin-like growth factor-1 (IGF-1) negative feedback have
been shown to correct metabolic abnormalities and body composition changes associated with
low GH levels with fewer side effects, particularly with regard to hyperglycemia [5–8].
Tesamorelin (Theratechnologies, Inc., Montreal, Quebec, Canada) is a synthetic analogue
of human GHRH that increases basal and pulsatile secretion of GH [9–10]. A hexenoyl moiety
has been anchored at the N-terminus of the 44 amino acid sequence of human GHRH, result-
ing in enhanced stability in serum as compared to natural human GHRH. Because GH has
been shown to worsen glucose tolerance in some subjects, including those receiving highly
active antiretroviral therapy (HAART) [11], a randomized, parallel, placebo-controlled, multi-
center study was carried out to assess the safety of tesamorelin in only subjects with type 2 dia-
betes mellitus.
Methods
The protocol for this study and supporting CONSORT checklist are available as supporting
information: see S1 CONSORT checklist and S1 Protocol.
Study design
Patients with stable type 2 diabetes were recruited at 5 sites in the US between February and
November 2002. After screening and a 14-day lead-in period to establish and characterize
daily dietary patterns and blood measurements, patients diabetes were randomly assigned to
receive either placebo, tesamorelin 1 mg, or tesamorelin 2 mg, administered by subcutaneous
injection for 12 weeks (Fig 1). The study included a 4-week follow-up period to monitor for
adverse events. Randomization was stratified on the basis on insulin use. To maintain balance
of treatment assignments among insulin use groups (insulin use, no insulin use), eligible
patients were randomly allocated in balanced blocks (1:1:1 ratio) to one of the 3 treatment
groups according to computer generated randomization codes, which were prepared by a stat-
istician who was not otherwise involved in the study. Patients and investigators were unaware
of assignments to study groups. Tesamorelin and matching placebo were provided as lyophi-
lized powder for reconstitution in sterile water. Inclusion criteria included: male or postmeno-
pausal or surgically sterilized female subjects,50 years of age; diagnosis of type 2 diabetes for
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3 months before screening; on stable diabetes treatment regimens (oral hypoglycemics
with or without insulin) for2 months before screening; screening and pre-randomization
HbA1c <10% (baseline range: 5.3–9.5%) and body mass index (BMI) between 25 and 38 kg/
m2. Exclusion criteria included: positive mammography (if female) or prostate-specific antigen
(PSA) or prostate examination for cancer (if male); use of oral or parenteral glucocorticoids in
the 30 days before screening; use of any experimental or marketed GH, GH secretagogue, IGF-
1, or insulin-like growth factor binding protein-3 (IGFBP-3) in the previous 6 months; history
of or presence of active concomitant conditions or diseases; documented hypopituitarism, his-
tory of pituitary tumor/surgery, head irradiation, or severe head trauma; and current or history
of cancer.
Metabolic measurements
Fasting blood samples were drawn at baseline and at Weeks 1, 4, 8, and 12 of treatment for
measurement of fasting glucose and IGF-1 levels. Samples were drawn at baseline and at
Weeks 8 and 12 for determination of triglyceride, total cholesterol, low-density lipoprotein
(LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol levels. Fasting blood sam-
ples were drawn at baseline and at Weeks 4, 8, and 12 for determination of glycosylated hemo-
globin (HbA1c) level. An Oral Glucose Tolerance Test (OGTT) using 75 grams of glucose was
performed at baseline and after 1, 4, 8, and 12 weeks of treatment. The subjects had fasted
overnight prior to the OGTT. Paired insulin and glucose measurements were performed at 0
minute (before ingestion of 75 grams of glucose) and every 30 minutes during the OGTT.
Patients were instructed to withhold insulin and sulfonylurea hypoglycemic medications on
Fig 1. CONSORT flow diagram of the clinical study. Patient enrollment and outcomes.
https://doi.org/10.1371/journal.pone.0179538.g001
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the days in which OGTT was performed. Insulin sensitizers were not withheld. Home blood
glucose was obtained four times per day (before breakfast, lunch, and dinner, and at bedtime)
using a standard blood glucose meter. The glucose values were downloaded into a computer-
ized recall system. The measurements were used to calculate mean daily blood glucose values.
In addition, the number of dose adjustments per week for insulin and/or oral hypoglycemic
agents, as well as control of diabetes, was recorded.
Laboratory methods
All metabolic parameters were measured centrally at Esoterix Inc. (Calabasas Hill, CA). Fast-
ing glucose and insulin, HbA1c, total cholesterol, HDL cholesterol, LDL cholesterol, and tri-
glycerides were determined using standard laboratory assays. Plasma IGF-1 was measured
using radioimmunoassay (RIA) kits, with a lower limit of detection of 10 ng/mL.
Body composition measurements
Anthropometric measurements were determined by standard techniques. Body weight (BW)
was measured to the nearest 0.1 kg and height (H) to the nearest millimeter. Body mass index
(BMI) was calculated as BW (kg) divided by H (m2). Waist circumference was measured in the
standing position midway between the lower rib margin and the iliac crest using a tape mea-
sure. Body fat was estimated from measurements with Lange skin-fold calipers at biceps, tri-
ceps, subscapular, and iliac crest sites, as previously described [12].
Compliance
Subjects recorded their compliance with the treatment regimen in diaries. Compliance was
checked by counting the number of empty vials returned at each visit.
Statistical analyses
The primary endpoint of the study was the relative insulin response over the 12-week treat-
ment period. Relative insulin response was defined as the ratio of the incremental response in
plasma insulin to that of plasma glucose during the first 30 minutes of the OGTT, divided by
basal insulin, i.e., [delta Insulin (30 min- 0 min)/delta glucose (30 min- 0 min)]/basal insulin,
as previously described [13].
Secondary endpoints included changes from baseline to Week 12 in HbA1c, changes in
mean daily blood glucose concentrations compared to values from the 14-day lead in period,
as well as changes in the number of dose adjustments per week for insulin and/or oral hypogly-
cemic agents, and the number of patients with a change in the control of diabetes.
Sample size was planned to assess a 15% change in the relative insulin response in each of
the treatment groups and a constant standard deviation of 0.20, based on data from a previous
study involving diabetic subjects [14]. Statistical analyses were performed by Charles River
Laboratories Clinical Services (Wilmington, NC, USA) using SAS statistical software (SAS
Institute Inc., Cary, NC). Additional parametric statistical analyses were performed by Excel-
sus Statistics Inc. (Montreal, Quebec, Canada). Baseline characteristics were compared using
Fisher’s Exact test for categorical variables and linear mixed effect models for continuous vari-
ables. Changes from baseline in relative insulin response and HbA1c were compared among
the treatment groups using a repeated-measures analysis of variance (ANOVA) model with
treatment, insulin use, and study center as between-subject main effects and time as within-
subject main effect. The within-subject random errors associated with repeated-measures
across time were modeled using the covariance structure that minimizes the Aikaki’s criterion
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(AICC). The same approach was used for anthropometric and metabolic parameters. Glu-
cose and insulin levels from the OGTT (change from pre-ingestion) were analyzed using a
repeated-measures analysis of covariance (ANCOVA) model with pre-ingestion at baseline
(Week 0) as the covariate, with treatment, insulin use, study center, Week (Weeks 1, 4, 8, 12)
and Time Point (30, 60, 90, 120, 150 and 180 minutes) as factors and subject as random effect.
Main daily home blood glucose change from baseline was analyzed using a repeated measures
ANOVA model with treatment, insulin use, study center, Week (1 to 14) and time of the day
(Breakfast, Lunch, Dinner and Bedtime) as factors and subject as random effect. A simple
within-subject correlation was chosen for those analyses because of the complexity of the two-
level time variable (Weeks and Time points/Time of the day). The graphical analysis of the
residuals indicated that this model was appropriate. Unless otherwise specified, all statistical
tests were two-sided at a 0.05 significance level without corrections for multiple outcomes or
multiple comparisons. The primary treatment comparison was the comparison of the two doses
(1 mg and 2 mg tesamorelin). The safety population, which was defined as all subjects who were
randomized and received at least one dose of study medication, was the primary population for
analysis. As the primary objective of the study was to assess the safety of tesamorelin, no method
was performed to impute missing data in the primary analysis of the primary endpoint.
Ethics statement
The protocol of this study was approved by the institutional review board (IRB) used by the
participating sites. Three sites used the Western Institutional Review Board [WIRB] (original
approval date: January 16, 2002) and two sites used local IRBs: the MRI Institutional Review
Board at Washington Hospital Center (original approval date: January 17, 2002) and the Insti-
tutional Review Board for Health Science Research at the University of Virginia (original
approval date: May 22, 2002). All patients provided institutionally approved, written informed
consent. The study was registered at clinicaltrials.gov (NCT01264497). There was a delay in
study registration due to administrative oversight. The authors confirm that all ongoing and
related trials for this drug/intervention are registered.
Results
Subject baseline characteristics and disposition
Of fifty five (55) patients assessed for eligibility, 53 received at least one dose of study treatment
and were included in the analyses (16 patients randomized to placebo, 18 to tesamorelin 1 mg,
and 19 to tesamorelin 2 mg). The proportion of patients completing the study was not statisti-
cally significantly different among the placebo (69%), tesamorelin 1 mg (78%), and tesamore-
lin 2 mg (79%) groups. No patients withdrew from the study due to loss of diabetes control.
Patient enrollment and outcomes are shown in Fig 1.
As shown in Table 1, there were no significant differences among treatment groups in
demographics or baseline characteristics, except for a statistically significant higher mean fast-
ing insulin level in the tesamorelin 1 mg group. Most patients (74%) did not use insulin, while
26% were insulin users.
Relative insulin response
Mean relative insulin response following oral ingestion of glucose increased slightly from base-
line in all groups at all time points over the 12-week treatment period. There were no signifi-
cant differences between groups in treatment or time effect (Table 2). At Week 12, changes
from baseline in mean relative insulin response were 0.02±0.08, 0.05±0.37, and 0.13±0.56 L/
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pmol for the placebo, tesamorelin 1 mg, and tesamorelin 2 mg groups, respectively. The rela-
tive insulin response for most patients, however, remained below mean values reported for
normoglycemic individuals (1.85 ±1.18 L/mmol) (data not shown).
Glucose levels during the OGTT
Glucose levels during the OGTT were not significantly different between the treatment groups
over the 12-week treatment period. As shown in Table 3, changes in glucose levels at 30 and
Table 1. Demographics and baseline characteristics of the patients.
Placebo (N = 16) Tesamorelin 1mg (N = 18) Tesamorelin 2mg (N = 19) P value
Age (years) 63.1±7.0 59.5±7.9 60.3±6.7 0.40
Gender (n, %)
Male 12 (75) 9 (50) 14 (74) 0.22
Female 4 (25) 9 (50) 5 (26)
Race (n, %)
Caucasian 12 (75) 7 (39) 10 (53) 0.25
Hispanic/Latino 3 (19) 7 (39) 6 (32)
Asian/Pacific Islander 0 3 (17) 3 (16)
Other 1 (6) 1 (6) 0
Weight (kg) 91±15 91±16 95±18 0.64
BMI (kg/m2) 30.3±4.2 32.2±4.2 32.1±4.2 0.32
Fasting glucose (mmol/L) 6.9±2.5 8.7±2.4 7.7±1.4 0.09
Fasting insulin (pmol/L) 86±41 168±12 100±68 0.02
Relative Insulin Response (L/pmol) 0.26±0.27 0.15±0.27 0.07±0.45 0.34
HbA1c (%) 6.8±0.9 7.4±0.9 6.9±0.7 0.16
Insulin status (n, %)
Users 4 (25) 5 (28) 5 (26) >0.99
Non-users 12 (75) 13 (72) 14 (74)
Abbreviations: BMI, body mass index. Data are presented as mean ± SD unless otherwise specified.
https://doi.org/10.1371/journal.pone.0179538.t001
Table 2. Changes from baseline in relative insulin response (L/pmol) over the 12-week treatment period.
Placebo (N = 16) Tesamorelin 1mg (N = 18) Tesamorelin 2mg (N = 19)
Baseline 0.26 (0.27) 0.15 (0.27) 0.07 (0.45)
Week 1
Change from baseline 0.06 (0.34) 0.00 (0.28) 0.16 (0.58)
Week 4
Change from baseline 0.03 (0.26) 0.08 (0.21) 0.15 (0.45)
Week 8
Change from baseline 0.10 (0.33) 0.12 (0.17)b 0.11 (0.48)
Week 12
Change from baseline 0.02 (0.08) 0.05 (0.37) 0.13 (0.56)
P-value Treatmenta
0.71
P-value Week 0.80
Data are reported as mean (SD)
aP-values from a repeated mesures ANOVA on relative insulin response with main effects for treatment, insulin use (Yes/No), week and center. Within-
patient covariance was modeled using the Unstructured covariance structure.
https://doi.org/10.1371/journal.pone.0179538.t002
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120 minutes post-glucose load during the OGTT were similar between the 3 groups at Weeks
0 (baseline), 1, 4, 8, and 12. At Week 12, the post-glucose load values at 120 minutes were 7.8
±2.9, 6.7±3.2, and 8.7±3.6 mmol/L for the placebo, tesamorelin 1 mg, and tesamorelin 2 mg,
respectively. As expected with the OGTT, glucose levels increased in all the treatment groups
30 and 60 minutes following ingestion of the 75-g glucose load.
Insulin levels during the OGTT
There were no significant treatment differences in the change from pre-glucose load in insulin
levels over the 12-week treatment period (Table 4). Time-dependent changes in insulin levels
were observed among the groups. As seen with glucose, mean insulin levels at 30 and 120 min-
utes post-glucose load were significantly higher in all the treatment groups compared to pre-
glucose load levels over the 12-week treatment period. At Week 12, mean insulin levels at 120
minutes post-glucose load were 137.4±179.5, 159.9±165.8, and 123.9±124.6 pmol/L for the pla-
cebo, tesamorelin 1 mg and tesamorelin 2 mg groups, respectively.
Fasting glucose levels
Fasting glucose levels were comparable across treatment groups at baseline. There were no sig-
nificant differences among groups in fasting glucose over the 12-week treatment period, using
Table 3. Glucose levels (mmol/L) pre-ingestion (0 minute) and changes from pre-glucose ingestion values at 30 and 120 minutes during the
OGTT.
Placebo (N = 18) Tesamorelin 1mg (N = 19) Tesamorelin 2mg (N = 16)
Week 0 (Baseline)
Pre-glucose ingestion 6.9 (2.4) 8.4 (2.2) 7.6 (1.4)
Change at 30 minutes 5.6 (2.1) 4.9 (2.0) 5.1 (2.7)
Change at 120 minutes 7.4 (2.3) 7.2 (2.6) 8.9 (1.9)
Week 1
Pre-glucose ingestion 7.0 (1.6) 9.0 (2.4) 8.0 (2.0)
Change at 30 minutes 5.2 (1.9) 5.2 (2.3) 5.5 (2.1)
Change at 120 minutes 6.8 (2.5) 6.8 (2.5) 8.5 (2.2)
Week 4
Pre-glucose ingestion 6.6 (1.7) 9.1 (2.5) 8.5 (1.7)
Change at 30 minutes 5.9 (2.8) 4.7 (2.3) 5.6 (1.0)
Change at 120 minutes 6.5 (2.2) 7.5 (3.8) 8.6 (2.3)
Week 8
Pre-glucose ingestion 7.2 (1.9) 7.8 (1.9) 8.2 (1.5)
Change at 30 minutes 5.9 (2.9) 5.0 (1.7) 5.5 (2.3)
Change at 120 minutes 8.1 (3.4) 6.3 (3.4) 8.2 (2.5)
Week 12
Pre-glucose ingestion 6.9 (1.7) 8.0 (2.2) 7.7 (2.4)
Change at 30 minutes 5.4 (2.7) 5.0 (1.6) 5.6 (1.9)
Change at 120 minutes 7.8 (2.9) 6.7 (3.2) 8.7 (3.6)
P-value Treatmenta 0.28
P-value Weeka 0.28
P-value Time Pointa <0.001
Data are reported as mean (SD)
aP-values from a repeated measures ANCOVA on OGTT Glucose change from pre-ingestion with baseline OGTT glucose (Week 0) as covariate and
treatment, insulin use (Yes/No), time, minute (30, 60, 90, 120, 150 and 180), and center as factors and subject as random effect.
https://doi.org/10.1371/journal.pone.0179538.t003
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the repeated measures ANOVA. Changes from baseline in fasting glucose (mean±SD) were as
follows: Week 1: 0.2±1.5, 0.8±2.8, 0.9±2.4 mmol/L; Week 4: 0.4±3.4, 0.2±2.0, 1.0±1.3 mmol/L;
Week 8: 0.3±3.1, -0.5±1.4, 0.9±1.2 mmol/L; Week 12: -0.6±2.1, -0.7±1.5, 0.1±2.4 mmol/L, for
placebo, tesamorelin 1 mg, and tesamorelin 2 mg, respectively, p = 0.44. There was a border-
line effect of time on fasting glucose (p = 0.06), with glucose values higher in the tesamorelin 2
mg group at Weeks 4 and 8 compared to values in the other groups.
Home glucose measurements
Overall, no significant differences were observed among treatment groups in the change from
the lead-in period (baseline) in blood glucose measurements (Table 5). The time of the day
had a significant effect on blood glucose measurements. As shown in Table 5, before-lunch
glucose levels tended to increase from the lead-in period in the tesamorelin 2 mg group com-
pared to the placebo and tesamorelin 1 mg groups. In addition, time-dependent (Week)
changes in blood glucose levels were seen among the groups. The before-lunch changes in glu-
cose levels differed between groups at Weeks 1, 4, and 8. Mean changes from baseline in blood
glucose were overall minimal (<1.1 mmol/L, except for the tesamorelin 2 mg before lunch)
and were not considered as clinically meaningful.
Table 4. Insulin (pmol/L) levels pre-glucose ingestion (0 minute) and changes from pre-glucose ingestion values at 30 and 120 minutes during the
OGTT.
Placebo (n = 16) Tesamorelin 1 mg (n = 18) Tesamorelin 2 mg (n = 19)
Week 0 (Baseline)
Pre-glucose ingestion 86.1 (40.9) 168.1 (111.7) 99.5 (67.7)
Change at 30 minutes 115.7 (105.7) 65.4 (78.2) 87.0 (99.30
Change at 120 minutes 140.1 (106.6) 163.3 (199.5) 163.1 (171.8)
Week 1
Pre-glucose ingestion 84.6 (44.7) 159.7 (99.0) 99.3 (52.9)
Change at 30 minutes 119.7 (100.7) 89.9 (118.5) 102.4 (142.0)
Change at 120 minutes 132.5 (122.3) 161.2 (147.7) 162.4 (191.2)
Week 4
Pre-glucose ingestion 83.6 (33.1) 136.4 (73.8) 93.3 (63.0)
Change at 30 minutes 114.1 (84.3) 77.6 (101.2) 98.4 (88.3)
Change at 120 minutes 149.3 (139.7) 158.9 (135.2) 132.7 (126.3)
Week 8
Pre-glucose ingestion 95.4 (41.2) 136.4 (83.5) 108.5 (64.8)
Change at 30 minutes 126.7 (142.0) 119.0 (128.8) 89.0 (97.1)
Change at 120 minutes 102.6 (127.3) 194.2 (158.7) 135.6 (85.8)
Week 12
Pre-glucose ingestion 86.6 (37.1) 154.2 (100.9) 92.2 (44.5)
Change at 30 minutes 85.6 (103.7) 103.4 (124.3) 93.8 (75.3)
Change at 120 minutes 137.4 (179.5) 159.9 (165.8) 123.9 (124.6)
P-value Treatmenta 0.80
P-value Weeka 0.04
P-value Time Pointa <0.001
Data are reported as mean (SD)
aP-values from a repeated measures ANCOVA on OGTT Glucose change from pre-ingestion with baseline OGTT glucose (Week 0) as covariate and
treatment, insulin use (Yes/No), week, time point (30, 60, 90, 120, 150 and 180 minutes), and center as factors and subject as random effect.
https://doi.org/10.1371/journal.pone.0179538.t004
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HbA1c levels
The repeated-measures analysis across time did not reveal an overall treatment effect for
HbA1c. The mean changes (SD) from baseline to Week 12 in HbA1c were -0.5 (0.8), -0.6 (0.8),
and 0.1 (0.4) % for the placebo, tesamorelin 1 mg, and tesamorelin 2 mg, respectively (Table
6). The change in HbA1c was statistically significantly different between the placebo and tesa-
morelin 2 mg groups at Week 12 (p<0.05).
Changes in diabetic regimen and diabetes control
During the study, few patients changed medications from the diabetic regimen used at screen-
ing and treatment groups were not significantly different in the frequency of changes to
Table 5. Changes from lead-in period (baseline) in mean blood home glucose levels (mmol/L) over the 12-Week treatment period.
Placebo (N = 16) Tesamorelin 1mg (N = 18) Tesamorelin 2mg (N = 19)
Before Breakfast
Lead-in period 7.1 (1.3) 8.2 (1.5) 7.8 (1.7)
Change from Lead-in Period
Week 1 0.6 (1.3) 0.6 (1.6) 0.6 (1.1)
Week 4 0.4 (1.0) 0.4 (1.8) 1.0 (1.2)
Week 8 0.6 (1.2) 0.3 (1.4) 0.6 (1.3)
Week 12 0.9 (0.9) 1.0 (1.7) 0.7 (1.5)
Before Lunch
Baseline 7.2 (1.5) 8.8 (1.9) 8.4 (1.9)
Change from Lead-in Period
Week 1 0.0 (1.7) 0.9 (1.9) 1.6 (1.6)
Week 4 0.1 (1.1) 0.4 (2.1) 1.3 (1.4)
Week 8 0.4 (1.0) 0.3 (2.4) 1.0 (1.4)
Week 12 0.6 (1.5) 1.0 (2.6) 0.7 (1.1)
Before Dinner
Baseline 7.1 (1.6) 9.3 (1.7) 8.3 (1.8)
Change from Lead-in Period
Week 1 0.3 (1.4) -0.1 (2.4) 1.1 (1.4)
Week 4 0.7 (1.4) -0.0 (2.1) 0.8 (1.7)
Week 8 0.3 (1.0) -0.1 (2.9) 0.2 (1.4)
Week 12 0.6 (1.6) -0.0 (2.4) 0.3 (1.7)
Bedtime
Baseline 9.2 (2.3) 9.8 (1.9) 9.4 (1.6)
Change from Lead-in Period
Week 1 0.6 (1.7) 0.6 (2.8) 0.8 (2.4)
Week 4 0.4 (2.1) -0.0 (2.9) 0.3 (1.6)
Week 8 0.1 (2.0) -0.8 (3.0) 0.8 (1.6)
Week 12 -0.5 (1.6) 0.3 (3.1) 0.8 (2.0)
P-value Treatmenta 0.77
P-value Time of the Daya <0.0001
P-value Weeka 0.02
Dare are reported as mean (SD). The mean daily blood glucose level for a time period e.g., lead-in, Week 1, etc. . .) is defined as the average of the daily
results for that time period.
aP-values from a repeated measures ANOVA on mean home glucose levels change from baseline with treatment, insulin use (Yes/No), Week (1 to 12),
Time of day (Breakfast, Lunch, Dinner and Bedtime), and center as factors and subject as random effect.
https://doi.org/10.1371/journal.pone.0179538.t005
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diabetic regimens. After 12 weeks of treatment, there was no significant difference among
treatment groups in the percentage of patients with investigator-assessed changes in diabetes
control. Compared to baseline, diabetes control did not worsen in any patients and was rated
better in 6 (55%), 5 (36%), and 7 (47%) patients in the placebo, tesamorelin 1 mg, and tesamor-
elin 2 mg groups, respectively (p = 0.58). No patients withdrew from the study due to loss of
diabetes control.
Serum lipid parameters
The repeated-measures ANOVA did not reveal any statistically significant differences among
the treatment groups in triglycerides, total cholesterol, HDL cholesterol, non–HDL choles-
terol, LDL-cholesterol, and triglycerides (Table 6). When compared to baseline, total choles-
terol (-0.3±0.6 mmol/L, p<0.05 vs. placebo) and non-HDL cholesterol (-0.3±0.5 mmol/L,
p<0.05 vs. placebo) significantly decreased within the tesamorelin 2 mg group at Week 12.
HDL cholesterol and triglyceride levels did not significantly change from baseline in any of the
treatment groups (Table 6).
IGF-1 and IGFBP-3 levels
The changes from baseline in IGF-1 were significantly different among the treatment groups
Treatment with tesamorelin was associated with a dose-dependent increase in IGF-1 from
baseline to Week 12 (mean change from baseline: 33 and 66 ng/mL for the tesamorelin 1 mg
and 2 mg groups, respectively, p<0.05 vs. placebo for both groups) (Table 5). IGFBP-3 also sig-
nificantly increased from baseline in the tesamorelin 2 mg group at Week 12 (mean change
from baseline: 0.4 mg/L, p<0.05 vs. placebo) (Table 5).
Table 6. Changes from baseline in anthropometric and metabolic parameters at Week 12.
Placebo (N = 16) Tesamorelin 1 mg (N = 18) Tesamorelin 2 mg (N = 19)
Baseline Δ Baseline Δ Baseline Δ P-value ¶
Weight (kg) 91±15 -2±3 91±16 -0±2 95±18 -1±3 0.08
BMI (kg/m2) 30.3±4.2 -0.7±1.1 32.2±4.2 -0.1 ±0.8 32.1±4.2 -0.4±1.0 0.62
% Body fat 35±7 -0±2 39±7 -1±2 37±7 -1±4 0.96
Waist circumference (cm) 104±12 -2.0±3.8 102±12 -0.3±5.3 106±13 -0.3±5.7 0.29
IGF-I (ng/mL) 131±49 -4±19 102±39 33±37 ‡ 111±31 66±64 § 0.02
IGFBP-3 (mg/L) 2.4±0.7 -0.1±0.3 2.3±1.0 0.5±0.7 2.4±0.6 0.4±0.7 § 0.12
Fasting glucose (mmol/L) 6.9±2.5 -0.6±2.1 8.7±2.4 -0.7±1.5 7.7±1.4 0.1±2.4 0.44
Relative insulin response (L/pmol) 0.26±0.27 0.02±0.10 0.15±0.27 0.05±0.37 0.07±0.45 0.13±0.56 0.71
HbA1c (%) 6.8±0.9 -0.5±0.8 7.4±0.9 -0.6±0.8 6.9±0.8 0.1±0.4 § 0.11
Triglycerides (mmol/L) 2.3±1.3 0.5±1.8 2.3±1.4 -0.3±1.2 2.0±0.9 -0.1±1.1 0.65
Total cholesterol (mmol/L) 4.6±0.8 0.3±0.6 4.6±0.9 0.2±0.4 4.7±1.1 -0.3±0.6 § 0.06
HDL cholesterol (mmol/L) 1.1±0.3 0.1.2±0.2 1.2±0.4 0.1±0.1 1.2±0.4 -0.0±0.2 0.56
LDL cholesterol (mmol/L) 2.4±0.7 0.1±0.5 2.5±0.7 0.3±0.5 2.7±0.9 -0.3±0.6 0.15
Non-HDL cholesterol (mmol/L) 3.6±0.9 0.2±0.5 3.5±0.9 0.1±0.4 3.5±1.1 -0.3±0.5 § 0.10
Abbreviations: IGF-1, insulin-like growth factor-1; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein.
Data are presented as mean ± SD
¶ P-values for the comparison between the changes from baseline in the 3 treatment groups from the repeated-measures ANOVA with main effects for
treatment, insulin use (Yes/No), time and center.
‡ p<0.05 for the comparison between the changes from baseline in the tesamorelin 1 mg group and the placebo group.
§ p<0.05 for the comparison between the changes from baseline in the tesamorelin 2 mg group and the placebo group.
https://doi.org/10.1371/journal.pone.0179538.t006
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Body composition
At Week 12, there were no statistically significant differences among treatment groups in
weight, BMI, percent body fat, and waist circumference (Table 5).
Adverse events
Adverse events were reported in 50% of patients in the placebo group, 39% of patients in the
tesamorelin 1 mg, and 58% of patients in the tesamorelin 2 mg group. Adverse events that
were reported in more than one patient in the treated groups were nausea (n = 2 in the tesa-
morelin 2 mg group, 11%), diarrhea (n = 2 in the tesamorelin 1 mg group, 11%), generalized
weakness (n = 2 in the tesamorelin 1 mg group, 11%), fatigue (n = 2 in the tesamorelin 2 mg
group, 11%), headache (n = 2 in the tesamorelin 2 mg group, 11%), upper respiratory tract
infection (n = 2 in the tesamorelin 2 mg group, 11%), and light-headedness (n = 2 in the tesa-
morelin 1 mg group, 11%). Most adverse events were mild in severity. Anti-tesamorelin anti-
bodies were not detected in any patient after 12 weeks of treatment. During the 4-week follow-
up period, 12 AEs were reported in 8 subjects (15%), including 2 subjects in the tesamorelin 1
mg group (cough, dry skin, popular rash) and 3 subjects each in the placebo (anemia, increased
serum potassium, upper respiratory tract infection, diaphoresis, pruritus, urinary tract infec-
tion) and tesamorelin 2 mg (hypoesthesia, sinusitis, rash) groups. None was reported by more
than one subject, and all were mild or moderate in severity. The only AE during the follow-up
period that was considered possibly related to study drug was mild hypoesthesia occurring in a
subject in the tesamorelin 2 mg group. There were no deaths or serious adverse events during
the study or follow-up period.
Compliance
Mean compliance was 99.5, 98.5 and 97.0% in the placebo, tesamorelin 1 mg and tesamorelin
2 mg groups, respectively.
Discussion
The use of GH can lead to worsening glucose tolerance in patients with IGT and/or overt dia-
betes [15]. Most of the GH adverse effects are believed to be linked to supraphysiological
increases in GH and IGF-1 levels [16]. Therefore, it has been hypothesized that therapeutic
strategies to increase GH and IGF-1 levels within the normal physiological range would result
in fewer side effects. Because tesamorelin, a stabilized GHRH analogue, has been previously
shown to stimulate GH secretion in a physiological manner [9–10], this study was conducted
in patients with type 2 diabetes to assess its potential effects on insulin sensitivity and diabetes
control. The results of this study showed that once daily subcutaneous administration of tesa-
morelin for 12 weeks resulted in a dose-dependent increase in IGF-1, an integrated measure of
GH secretion, which remained within the normal reference ranges for the patients’ age groups.
More important, the results demonstrate that tesamorelin did not alter the relative insulin
response of patients, thus indicating that the drug did not significantly affect glucose tolerance
or insulin sensitivity. Our data showing increases from baseline in fasting glucose in the tesa-
morelin 2 mg group at Weeks 4 and 8, but not at Week 12 suggest a transient increase in fast-
ing glucose following administration of tesamorelin. This finding is in agreement with recent
data from Stanley et al. [17] demonstrating initial increases in fasting glucose in HIV-infected
patients treated with tesamorelin, which were reversed after 6 months of treatment, with glu-
cose returning to baseline values. Home blood glucose levels increased before lunch in the tesa-
morelin 2 mg group at Weeks 1, 4, and 8. However, the increases were mild and of no clinical
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significance. Our data indicate that HbA1c slightly increased from baseline in the tesamorelin
2 mg group at Week 12. It is possible that the slight increase in HbA1c seen at Week 12 in the 2
mg tesamorelin group could reflect the increases in fasting glucose observed at Weeks 4 and 8.
Alternative reasons for the observed increase in HbA1c in the 2 mg tesamorelin group could be
the relatively small study’s sample size or changes in pharmacotherapy. Of note, control of dia-
betes, as assessed by the investigator, was improved at the end of the study in approximatively
50% of patients receiving tesamorelin 2 mg. A recent study showed that administration of tesa-
morelin to HIV-infected patients with excess abdominal fat for 52 weeks did not affect glucose
parameters, including fasting glucose, 2-hour glucose on OGTT, fasting insulin, and HbA1c
[18]. Nonetheless, because GH may induce glucose intolerance in some individuals, patients
receiving ongoing treatment with tesamorelin should be monitored periodically for potential
changes in glucose metabolism [18].
Overall, our findings are in agreement with previous studies demonstrating that GHRH
analogues restore physiologic GH and IGF-1 levels without inducing insulin resistance and/or
hyperglycemia in various populations, including healthy middle-aged and elderly subjects [5,
7, 8], GH-deficient children [19], and patients with HIV-associated lipodystrophy [6]. In con-
trast, chronic administration of pharmacological or low doses of rhGH has been shown to neg-
atively affect glucose metabolism in GH-deficient children and adults [1, 20, 21], abdominally
obese subjects [22–23], and HIV-infected patients with wasting [24] or lipodystrophy [25–26].
Several studies have been conducted to investigate the mechanism underlying the induction
of insulin resistance by pharmacological doses of GH. Free fatty acids derived from GH-stimu-
lated lipolysis have been proposed to contribute to the diabetogenic properties of GH through
a mechanism involving an increase in hepatic glucose output and a decrease in peripheral
glucose oxidation according to the glucose-fatty acid cycle utilization, i.e. a switch from using
glucose to lipids [27]. Supporting this possibility are the results from Bramnert et al. [28] dem-
onstrating a close correlation between serum free fatty acids and the rate of lipid oxidation in
GH-deficient patients. The molecular mechanism by which chronic GH excess affects glucose
metabolism is not well defined. The results from several in vitro and in vivo studies suggest
that long-term exposure to GH may induce insulin resistance by several mechanisms, includ-
ing increased expression of cellular proteins that inhibit the insulin receptor signaling [29–30],
a decrease in the expression of several key proteins involved in carbohydrate metabolism, as
well as a decrease in the insulin-mediated activation of glycogen synthase in the liver and mus-
cle [31]. It is believed that the beneficial effect of GHRH analogues on glucose metabolism is
due to the fact that feedback inhibition of IGF-1 on GH secretion by the pituitary remains
intact, thus preventing adverse effects due to GH excess [11, 32, 33]. In agreement with this
possibility, our data show that mean IGF-1 levels remained within the normal range following
administration of tesamorelin to type 2 diabetic patients.
Treatment with tesamorelin for 12 weeks was associated with a significant decrease from
baseline in LDL cholesterol and non-HDL cholesterol, whereas other lipid parameters
remained unchanged. Our results are consistent with other studies in humans, which demon-
strated a significant reduction in plasma cholesterol after GH replacement therapy [3, 34]. The
available evidence indicates that GH may reduce plasma cholesterol levels by stimulating
hepatic LDL receptor expression [35–36] and/or by increasing the activity of acyl coenzyme A
cholesterol acyltransferase (ACAT), the hepatic rate-limiting enzyme in bile acid biosynthesis
[37]. Our data are at variance with previous results showing an increase in serum triglyceride
levels after short-term administration of rhGH [38–39]. This increase may be explained by
both an increased flux of free fatty acids to the liver and a direct stimulatory effect on the ester-
ification of oleic acid into triglycerides and phospholipids in hepatocytes [40].
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This study has some limitations. First, the sample size was relatively small; hence, the results
should be interpreted with caution. Further studies with a larger sample size are needed to vali-
date the findings of the current study. Second, although the duration of 12 weeks of treatment
was adequate to discern important changes in glycosylated hemoglobin (HbA1c), a study of
longer duration is necessary to gather important information about the long-term safety of
tesamorelin in patients with type 2 diabetes. Third, the study population consisted largely of
Caucasians, which may limit the generalization of the study. Fourth, potential changes in diet
and exercise were not objectively measured in the study subjects. Fifth, it is possible that the
adverse effects of tesamorelin on glucose tolerance may have been masked due to the concomi-
tant use of oral hypoglycemic agents. In addition, no correction was made for multiple out-
comes or multiple comparisons.
Overall, our data indicate that daily administration of tesamorelin for 12 consecutive weeks
to type 2 diabetic patients was not associated with significant changes in relative insulin
response and/or diabetes control. In addition, treatment with tesamorelin was associated with
improvements in lipid parameters.
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